EFNB2 and head and neck squamous cell carcinoma: Moreover, EphB4 and ephrinB2 gained increasing attention with regard to therapy resistance in different solid tumors such as head and neck squamous cell carcinoma (HNSCC), pancreatic adenocarcinoma (PDAC), and bladder urothelial carcinoma [6,7,8,9].